Tibolone and endometrial cancer: A cohort and nested case-control study in the UK

Drug Safety

Volumn 28, Issue 3, 2005, Pages 241-249

  De Vries, Corinne S ^a,b   Bromley, Susan E ^a   Thomas, Hilary ^a   Farmer, Richard D T ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b Postgraduate Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TIBOLONE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; GENERAL PRACTICE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE RATE RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNITED KINGDOM;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DEMOGRAPHY; ENDOMETRIAL NEOPLASMS; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORPREGNENES; ODDS RATIO; TIME FACTORS;

EID: 14944350750     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528030-00005     Document Type: Article

References (27)

1. Von Dadelszen P, Gillmer MDG, Gray MD, et al. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial®) therapy. Br J Obstet Gynaecol 1994; 101: 158-61
2. Office for National Statistics. Cancer registration statistics. England, 1992-2001 [online]. Available from URL: http:// www.statistics.gov.uk/statbase/ Product.asp?vlnk=8843 [Accessed 2004 Sep 30]
3. Parsons AK, Londono JL. Detection and surveillance of endometrial hyperplasia and carcinoma. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
4. Herbst AL. Neoplastic diseases of the uterus. In: Mishell DR, Stenchever MA, Droegemueller W, et al., editors. Comprehensive gynecology. 3rd ed. St Louis (MO): Mosby-Year Book Inc., 1997
5. Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
6. Bergman L, Beelen MLR, Gallee MPW, et al. Comprehensive Cancer Centres' ALERT Group: risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356: 881-7
7. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 275: 370-5
8. Tang B, Markiewicz L, Kloosterboer HJ, et al. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestogenic activity ratios of steroidal drugs. J Steroid Biochem Mol Biol 1993; 45: 345-51
9. Rymer JM. The effects of tibolone. Gynecol Endocrinol 1998; 12: 213-20
10. Bromley SE, de Vries CS, Farmer RDT. Utilisation of hormone replacement therapy in the United Kingdom: a descriptive study using the General Practice Research Database. Br J Obstet Gynaecol 2004; 111 (4): 369-76
11. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994; 101: 53-6
12. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas 1991; 13: 243-51
13. Meuwissen JHJM, Wiegerinck MAHM, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995; 21: 121-5
14. Garcia Rodriguez LA, Perez-Gutthann S, Jick S. The UK General Practice Research Database. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester. John Wiley & Sons Ltd, 2000
15. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 87: 36-40
16. Walley T, Mangani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-9
17. StataCorp. Stata Statistical Software: Release 8.0. College Station (TX): StataCorp LP, 2001
18. Hill DA, Weiss NS, Beresford SAA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456-61
19. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13
20. Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61
21. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131-7
22. De Vries CS, Bromley SE, Williams TJ, et al. Risk factors associated with endometrial cancer [abstract]. Pharmacoepidemiol Drug Saf 2001; 10: S84
23. Burger CW, Van Unnik GA, Kenemans P. Hormone replacement therapy and endometrial cancer. In: Genazzani AR, editor. Hormone replacement therapy and cancer: the current status of research and practice. London: The Parthenon Publishing Group, 2002
24. Davies AP, Oram D. Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125. Br J Obstet Gynaecol 1994; 101: 632-3
25. Dören M, Rübig A, Coelingh Bennink FJT, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6: 299-306
26. Wiegratz I, Sänger N, Kuhl H. Formation of 7-alpha-ethinyl estradiol during treatment with tibolone. Menopause 2002; 9: 293-5
27. Bodine PV, Harris HA, Lyttle CR, et al. Estrogenic effects of 7-alpha-methyl-17-alpha ethynynlestradiol: a newly discovered tibolone metabolite. Steroids 2002; 67: 68I-6